Blue Water Vaccines Inc to Present at World Vaccine Congress Washington 2022
April 11, 2022 09:56 ET
|
Blue Water Vaccines Inc.
BWV-101 - Universal Influenza Program: Developing a novel vaccine to protect against all influenza strains using groundbreaking mathematical models and research CINCINNATI, April 11, 2022 (GLOBE...
Ebvia Announces Positive Results Published in Nature for TMPRSS2 Inhibitor for the Prevention and Treatment of COVID-19
March 29, 2022 09:00 ET
|
Ebvia
SAN FRANCISCO, March 29, 2022 (GLOBE NEWSWIRE) -- Ebvia, a biotechnology developing simple-to-use therapeutics for the treatment and prevention of COVID-19, today announces the publication entitled...
Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones
March 23, 2022 16:05 ET
|
Cocrystal Pharma, Inc.
Commenced enrollment in Phase 1 trial with orally administered, broad-spectrum antiviral agent CC-42344 for the treatment of pandemic and seasonal influenza AAdvanced COVID-19 programs with the goal...
Blue Water Vaccines Announces Publication in Nano Research Supporting Novel S&P Vaccine Platform Versatility
March 22, 2022 07:00 ET
|
Blue Water Vaccines Inc.
Blue Water Vaccines has exclusive, global licensing rights to Cincinnati Children’s Hospital Medical Center’s novel virus-like particle (VLP) vaccine platform.The data supports BWV’s ongoing...
SAB Biotherapeutics to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
January 05, 2022 07:00 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Jan. 05, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces...
Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate
December 16, 2021 07:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety,...
SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus
December 01, 2021 07:00 ET
|
SAB Biotherapeutics, Inc.
Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated Second clinical proof of concept achieved by...
Stanford Scientists First To Identify New Cellular Correlates of Protection Against Influenza for an Oral Flu Vaccine Developed by Vaxart
November 18, 2021 16:02 ET
|
Vaxart, Inc.
STANFORD, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- A new Stanford study published in Cell Host and Microbe has demonstrated that VXA-A1.1, an investigational oral tablet flu vaccine under...
Lateral Flow Assays Market revenue to cross USD 11.7 Bn by 2027: Global Market Insights Inc.
November 03, 2021 06:30 ET
|
Global Market Insights, Inc
Selbyville, Delaware, Nov. 03, 2021 (GLOBE NEWSWIRE) -- The lateral flow assays market size is anticipated to record a valuation of USD 11.7 billion by 2027, according to the most recent study by...
7 Hills Pharma Announces the Completion of a Landmark Phase I Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines
November 01, 2021 15:08 ET
|
7 Hills Pharma
HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”), a clinical-stage drug development company bringing to market a platform of unique, first-in-concept oral small...